In a nutshell This study evaluated if the benefit of adding abiraterone acetate (Zytiga) + prednisone (Deltasone) to androgen-deprivation therapy (ADT) in treating metastatic, castration-sensitive prostate cancer (mCSPC) would be maintained in patients treated with ADT alone. This study concluded that this treatment...
Read More
In a nutshell This study investigated the effect of apalutamide (Erleada) on survival in patients with castrate-resistant prostate cancer (CRPC). This study found that apalutamide had a positive effect on the survival of these patients. Some background One treatment option for patients with prostate cancer is androgen deprivation therapy...
Read More
In a nutshell This study aimed to investigate the use of pembrolizumab (Keytruda) for prostate cancer (PCa). This study found that pembrolizumab was associated with a decline in prostate-specific antigen (PSA; a tumor marker for PCa). Some background Pembrolizumab is a type of immunotherapy. It works by triggering your...
Read More
In a nutshell This phase 2 study will investigate cryosurgical freezing (CF) and intratumoral combination immunotherapy (ITI) in advanced prostate cancer (PC). The main outcome will be the reduction in prostate specific antigen (PSA). This trial is recruiting in California and Michigan, US. The details Metastatic prostate cancer (PC) is an...
Read MoreIn a nutshell This trial is investigating the effectiveness of pembrolizumab (Keytruda) plus enzalutamide (Xtandi) in patients with prostate cancer. The primary outcome to be measured will be the absence of cancer on the prostate after it is surgically removed. This study is being conducted in Portland, OR. The details...
Read More
In a nutshell This study aims to examine the effectiveness of niraparib (Zejula) combined with hormone therapy and radiotherapy to treat patients with high-risk prostate cancer. The main outcome to be measured will be how long patients remain cancer-free. This study is recruiting in Philadelphia, PA. The details Prostate cancer occurs mostly...
Read More
In a nutshell This phase 1 trial will investigate the safety of an experimental drug, XmAb22841 (XmAb), to treat advanced cancer. The main outcome will be the safety and tolerability of XmAb. This study is recruiting in Georgia and Texas, USA. The details Advanced cancer can be difficult to treat. New drugs are being developed to...
Read More
In a nutshell This phase 1 trial will investigate the safety of an experimental drug, XmAb22841 (XmAb), to treat advanced cancer. The main outcome will be the safety and tolerability of XmAb. This study is recruiting in Georgia and Texas, USA. The details Advanced cancer can be difficult to treat. New drugs are being developed to address this. Immune...
Read More
In a nutshell This study aimed to evaluate ultra-hypofractionated radiation therapy (UHFRT). This study found that UHFRT is safe and effective in the treatment of prostate cancer. Some background One option for the treatment of prostate cancer is radiation therapy. Conventional radiation treatment (CRT) involves using small doses of radiation 5...
Read More
In a nutshell This study aimed to investigate long-term outcomes of radiation therapy after prostate surgery for prostate cancer. This study found that this is a safe treatment option for these patients. Some background Prostate surgery is a common treatment for prostate cancer (PCa). Intensity-modulated radiation therapy (IMRT) is another option....
Read More
In a nutshell This study aimed to investigate a surgical procedure used to treat prostate cancer, retzius sparing laparoscopic robotic-assisted radical prostatectomy (RS-RALP). This study found that RS-RALP had similar side-effects and outcomes to other robotic surgeries. Some background Prostate surgery is a treatment option for prostate cancer...
Read MoreIn a nutshell This phase 2 trial is examining the effectiveness and safety of sacituzumab govitecan (IMMU-132) in patients with metastatic castration-resistant prostate cancer (mCRPC) who are having cancer progression on abiraterone (Zytiga) or enzalutamide (Xtandi). The main outcome to be measured will be the PSA (a...
Read More
